 Prostatic Neoplasms, Castration-Resistant
"Prostatic Neoplasms, Castration-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Descriptor ID |
D064129
|
| MeSH Number(s) |
C04.588.945.440.770.500 C12.294.260.750.500 C12.294.565.625.500 C12.758.409.750.500
|
| Concept/Terms |
Prostatic Neoplasms, Castration-Resistant- Prostatic Neoplasms, Castration-Resistant
- Castration-Resistant Prostatic Neoplasm
- Neoplasm, Castration-Resistant Prostatic
- Neoplasms, Castration-Resistant Prostatic
- Prostatic Neoplasm, Castration-Resistant
- Prostatic Neoplasms, Castration Resistant
- Androgen-Insensitive Prostatic Neoplasms
- Androgen Insensitive Prostatic Neoplasms
- Androgen-Resistant Prostatic Neoplasms
- Androgen Resistant Prostatic Neoplasms
- Prostatic Neoplasms, Hormone Refractory
- Hormone Refractory Prostatic Neoplasms
- Prostatic Neoplasms, Androgen-Independent
- Androgen-Independent Prostatic Neoplasm
- Neoplasm, Androgen-Independent Prostatic
- Neoplasms, Androgen-Independent Prostatic
- Prostatic Neoplasm, Androgen-Independent
- Prostatic Neoplasms, Androgen Independent
- Prostatic Neoplasms, Androgen-Insensitive
- Androgen-Insensitive Prostatic Neoplasm
- Neoplasm, Androgen-Insensitive Prostatic
- Neoplasms, Androgen-Insensitive Prostatic
- Prostatic Neoplasm, Androgen-Insensitive
- Prostatic Neoplasms, Androgen Insensitive
- Prostatic Neoplasms, Androgen-Resistant
- Androgen-Resistant Prostatic Neoplasm
- Neoplasm, Androgen-Resistant Prostatic
- Neoplasms, Androgen-Resistant Prostatic
- Prostatic Neoplasm, Androgen-Resistant
- Prostatic Neoplasms, Androgen Resistant
- Androgen-Independent Prostatic Neoplasms
- Androgen Independent Prostatic Neoplasms
- Castration-Resistant Prostatic Neoplasms
- Castration Resistant Prostatic Neoplasms
Prostatic Cancer, Castration-Resistant- Prostatic Cancer, Castration-Resistant
- Cancer, Castration-Resistant Prostatic
- Cancers, Castration-Resistant Prostatic
- Castration-Resistant Prostatic Cancers
- Prostatic Cancer, Castration Resistant
- Prostatic Cancers, Castration-Resistant
- Androgen-Insensitive Prostatic Cancer
- Androgen Insensitive Prostatic Cancer
- Androgen-Resistant Prostatic Cancer
- Androgen Resistant Prostatic Cancer
- Prostatic Cancer, Hormone Refractory
- Hormone Refractory Prostatic Cancer
- Prostatic Cancer, Androgen-Independent
- Androgen-Independent Prostatic Cancers
- Cancer, Androgen-Independent Prostatic
- Cancers, Androgen-Independent Prostatic
- Prostatic Cancer, Androgen Independent
- Prostatic Cancers, Androgen-Independent
- Prostatic Cancer, Androgen-Insensitive
- Androgen-Insensitive Prostatic Cancers
- Cancer, Androgen-Insensitive Prostatic
- Cancers, Androgen-Insensitive Prostatic
- Prostatic Cancer, Androgen Insensitive
- Prostatic Cancers, Androgen-Insensitive
- Prostatic Cancer, Androgen-Resistant
- Androgen-Resistant Prostatic Cancers
- Cancer, Androgen-Resistant Prostatic
- Cancers, Androgen-Resistant Prostatic
- Prostatic Cancer, Androgen Resistant
- Prostatic Cancers, Androgen-Resistant
- Androgen-Independent Prostatic Cancer
- Androgen Independent Prostatic Cancer
- Castration-Resistant Prostatic Cancer
- Castration Resistant Prostatic Cancer
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms, Castration-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms, Castration-Resistant".
This graph shows the total number of publications written about "Prostatic Neoplasms, Castration-Resistant" by people in this website by year, and whether "Prostatic Neoplasms, Castration-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 2 | 0 | 2 | | 2014 | 3 | 1 | 4 | | 2015 | 6 | 0 | 6 | | 2016 | 4 | 0 | 4 | | 2017 | 2 | 1 | 3 | | 2019 | 7 | 0 | 7 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostatic Neoplasms, Castration-Resistant" by people in Profiles.
-
Chen Y, Li X, Mamouni K, Yang Y, Danaher A, White J, Liu H, Kucuk O, Gera L, Wu D. Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer. Prostate. 2020 09; 80(12):993-1005.
-
Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614.
-
Lee YG, Nam Y, Shin KJ, Yoon S, Park WS, Joung JY, Seo JK, Jang J, Lee S, Nam D, Caino MC, Suh PG, Chan Chae Y. Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. Cancer Lett. 2020 02 28; 471:72-87.
-
Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer BC. Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol. 2020 01; 38(1):1.e1-1.e10.
-
Joshi M, Stoykova GE, Salzmann-Sullivan M, Dzieciatkowska M, Liebman LN, Deep G, Schlaepfer IR. CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions. Cells. 2019 09 20; 8(10).
-
May MB, Glode AE. Apalutamide: A new agent in the management of prostate cancer. J Oncol Pharm Pract. 2019 Dec; 25(8):1968-1978.
-
Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist. 2019 09; 24(9):1149-e807.
-
Stoykova GE, Schlaepfer IR. Lipid Metabolism and Endocrine Resistance in Prostate Cancer, and New Opportunities for Therapy. Int J Mol Sci. 2019 May 28; 20(11).
-
Miller DR, Ingersoll MA, Chatterjee A, Baker B, Shrishrimal S, Kosmacek EA, Zhu Y, Cheng PW, Oberley-Deegan RE, Lin MF. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance. Free Radic Biol Med. 2019 08 01; 139:24-34.
-
McNamara MA, Oyekunle T, Chin BB, Oldan J, Anand A, Ritz M, Shantzer L, Anand M, Armstrong AJ, George DJ. Patterns of response and progression in bone and soft tissue during and after treatment with radium-223 for metastatic castrate-resistant prostate cancer. Prostate. 2019 07; 79(10):1106-1116.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|